An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

November 12, 2017

Conditions
Advanced Solid Tumors
Interventions
DRUG

E7820

"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."

DRUG

E7820

"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."

Trial Locations (6)

Unknown

Netherlands Cancer Institute, Amsterdam

University Medical Centre Utrecht, Utrecht

Beatson West of Scotland Cancer Centre, Glasgow

University College London Hospital, London

The Christie Hospital, Manchester

Sir Bobby Robson Cancer Trials Research Centre, Newcastle

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01773421 - An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter